This implies that passive immunization with tau antibodies is a viable therapeutic focus on and the CSF level of p-tau262/356 or of the microtubule binding area (MTBD) can serve as a practical biomarker of tau pathology to watch tau therapeutics in scientific trials.Various colleagues have produced the counterargument which the sensor cell reaction